

ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa)
("Aspen Holdings")
Registration number: 1985/002935/06
Share code: APN
ISIN: ZAE000066692
LEI: 635400ZYSN1IRD5QWQ94
and its subsidiaries (collectively "Aspen" or "the Group")

GROUP FINANCIAL RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2021

SALIENT RESULTS

Aspen reported the following salient results:

- Revenue from continuing operations increased by 4% (+10% in constant exchange rate ("CER")) to R19,4 billion (December 2020: R18,6 billion);
- Normalised EBITDA from continuing operations increased by 10% (+15% in CER) to R5,7 billion (December 2020: R5,2 billion);
- Normalised headline earnings per share from continuing operations increased by 21% (+26% in CER) to 816.4 cents (December 2020: 676,2 cents);
- Headline earnings per share from total operations increased by 37% (+43% in CER) to 777,2 cents (December 2020: 566,2 cents);
- Earnings per share from total operations increased by 32% (+37% in CER) to 736,2 cents (December 2020: 558,4 cents); and
- Aspen secures right to branded COVID-19 vaccine Aspenovax.

REGULATORY REQUIREMENTS

The contents of the short form announcement are the responsibility of the Board of directors of Aspen. The information in the short form announcement is a summary of the full announcement available on the Company's website at <https://www.aspenpharma.com/investor-information/> on 9 March 2022 and accordingly does not contain full or complete details. The full announcement can also be accessed online at <https://senspdf.jse.co.za/documents/2022/jse/isse/APN/HYresults.pdf>

The information in this announcement has been extracted from the unaudited interim financial results for the six months ended 31 December 2021, but the short-form announcement itself has not been reviewed by the Company's auditors. The unaudited interim financial results have been prepared under the supervision of the Group Chief Financial Officer, Sean Capazorio, CA(SA).

Any investment decisions by shareholders/investors should be based on the full announcement as released by the JSE and published on the Company's website, <https://www.aspenpharma.com>. The full announcement is also available at the Company's registered office (for inspection, at no charge, during office hours on any business day) and at the offices of the sponsor, Investec Bank Limited, from 10 March 2022 to 31 March 2022, both days inclusive. Copies of the full announcement may be requested by contacting Riaan Verster on telephone: +27(0)31 580 8624, email: rverster@aspenpharma.com.

For and on behalf of the Board

Kuseni Dlamini
Chairman Group

Stephen Saad
Group Chief Executive

Registered office: Building 8, Healthcare Park, Woodlands Drive, Woodmead, Sandton

Woodmead
9 March 2022

Sponsor: Investec Bank Limited